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Revisiting strategies to eliminate mother-to-child 
transmission of syphilis
Mother-to-child transmission of syphilis, so-called 
congenital syphilis, can result in adverse pregnancy 
outcomes such as fetal loss, stillbirth, neonatal death, 
preterm birth, low birthweight, and congenital 
anomalies.1 Roughly 1 million pregnant women are 
estimated to be infected with syphilis worldwide, with 
the highest prevalence in east and southern Africa.2 
Antenatal screening and treatment with a single dose 
of benzathine benzylpenicillin successfully cures both 
maternal and congenital syphilis and prevents adverse 
pregnancy outcomes due to syphilis.3
10 years have elapsed since the release of the WHO 
Strategy for the Global Elimination of Congenital 
Syphilis in 2007.4 This document called for political 
commitment and advocacy to address the issue of 
congenital syphilis through increasing access to and 
quality of maternal and newborn health services, 
increasing screening and treatment of pregnant women 
and their partners, and establishing surveillance, 
monitoring, and evaluation systems. In June, 2017, a 
meeting was organised by the WHO Department of 
Reproductive Health and Research and the Bill and 
Melinda Gates Foundation to review the progress that 
has been made in the elimination of congenital syphilis, 
to discuss existing tools (panel),5–16 and to identify 
challenges ahead.
The general consensus at the meeting was that little 
progress has been made in the elimination of congenital 
syphilis over the past decade because of several 
challenges. Communicating the burden of congenital 
syphilis has been challenging because adverse health 
outcomes, such as stillbirth, are not always attributed 
to congenital syphilis. Additionally, many awareness 
efforts have been unsuccessful because of the stigma 
surrounding syphilis and the poor visibility of important 
advocates and stakeholders, which gives the perception 
that congenital syphilis is not a major public health 
problem. The participants acknowledged that reframing 
screening of syphilis in pregnancy as a matter of healthy 
pregnancy and healthy infants would deliver a more 
positive message, which could ultimately help raise 
awareness and garner support for the elimination of 
mother-to-child transmission of syphilis.
Poor access to benzathine benzylpenicillin, the only 
recommended treatment for pregnant women with 
syphilis, is a major issue, with shortages reported 
in many parts of the world.17 This issue is further 
complicated by the absence of an easily administered 
paediatric formulation of benzathine benzylpenicillin, 
the fear of allergic reactions to the drug, and resistance 
to using the drug because of its intramuscular 
administration. The misperception that benzathine 
benzylpenicillin is an outdated drug that could be 
replaced by newer, more effective drugs (that might be 
orally administered) has led health-care professionals 
to select alternative, ineffective treatments. A penicillin 
allergy desensitisation protocol (in consideration for 
guideline development by WHO) could reduce the use 
of alternative treatments because of concerns related to 
allergic reactions. Alternative treatments to benzathine 
Panel: Tools to aid the screening, treatment, and elimination 
of congenital syphilis
Provider tools
• Antenatal-care syphilis testing recommendations5
• Rapid HIV and syphilis test interim guidance6
• Current and projected use of benzathine penicillin G (BPG) 
in maternal syphilis7
• Syphilis treatment guidelines8
• Congenital syphilis case definition9
• Staff training on BPG administration10
• Penicillin desensitisation protocol11
Advocacy tools
• Congenital syphilis elimination strategy4
• Partnerships with stakeholders
• WHO global strategy on sexually transmitted infections 
(STIs)12
• WHO global guidance on elimination of mother-to-child 
transmission13
• Investment case for eliminating mother-to-child 
transmission of syphilis14
Surveillance tools
• WHO congenital syphilis surveillance case definition9
• UNAIDS Global AIDS Monitoring system15
• WHO Global Health Observatory16
• WHO congenital syphilis estimation tool7
• Avenir Health Spectrum STI modelling tool
• WHO STI surveillance report9
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benzylpenicillin are needed, in particular an alternative 
oral regimen that could increase access to treatment in 
settings and among populations where administration 
of injections is not feasible.
An important advancement in the screening of 
syphilis is the fairly recent availability of rapid diagnostic 
tests, either for detection of antibodies to Treponema 
pallidum alone or jointly with detection of antibodies to 
HIV. A systematic review18 of these dual rapid diagnostic 
tests for HIV and syphilis found that, in most cases, the 
minimal criteria specified in the target product profile 
for a dual HIV and syphilis test were met and that dual 
testing was cost-effective, feasible to implement at the 
programme level, and acceptable to testing clients. The 
WHO Department of Reproductive Health and Research 
is developing formal guidelines for the use of these dual 
tests, including diagnostic algorithms for their use in 
various settings and prevalence levels, which builds on 
interim WHO guidance published in 2017.6
Four tools for the surveillance and monitoring of 
national and global burdens of maternal and congenital 
syphilis were reviewed and endorsed at the meeting. 
First, the WHO surveillance case definition, which includes 
the requirement for treatment of pregnant women 
diagnosed with syphilis with benzathine benzylpenicillin 
to prevent congenital syphilis, can align national-level 
surveillance case definitions for consistent case reporting 
and global congenital syphilis estimations.13 Second, 
countries can report maternal syphilis screening and 
treatment data and incidence of congenital syphilis to the 
Global AIDS Monitoring system operated by UNAIDS.15 
These data are used by WHO for national, regional, and 
global estimations of syphilis burden. Third, the Avenir 
Health Spectrum STI modelling tool allows programme 
staff to estimate the prevalence and incidence of sexually 
transmitted infections in their national adult population. 
The model, which is freely available online, contains 
country-level syphilis prevalence data for more than 
150 countries. Fourth, WHO has expanded the Microsoft-
Excel-based congenital syphilis estimation tool7 to allow 
national-level-programme staff to generate estimates of 
congenital syphilis incidence and averted adverse birth 
outcomes with treatment projected through to 2030.
Although an investment case for accelerated 
congenital syphilis elimination activities has been 
available since 2012,14 stakeholder support and 
investment in elimination remain to be secured for 
global congenital syphilis prevention. Screening and 
treatment of syphilis during pregnancy is highly cost-
effective, even in low-prevalence settings.19 A consensus 
was reached to prioritise activities to expand and ensure 
availability of benzathine benzylpenicillin for treatment 
of syphilis and to expand use of rapid diagnostic tests 
in antenatal-clinic settings. Support at the national 
level, increased cooperation between and within 
UN agencies, and broader stakeholder involvement 
in syphilis prevention are needed to make provider-
level screening and treatment common practice in 
antenatal-clinic settings. These activities  will determine 
the advances made in the next decade of congenital 
syphilis prevention and elimination.
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